Stifel raised the firm’s price target on Syndax (SNDX) to $46 from $45 and keeps a Buy rating on the shares. Despite modest consensus misses on Revuforj and Niktimvo sales weighing on shares, the firm is “incrementally” more positive and confident in the trajectory of the Revuforj, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax price target lowered to $37 from $40 at Jefferies
- Analyst Reiterates Buy on Syndax as Commercial Momentum Builds and Clinical Data Strengthens, Maintains $40 Price Target
- Syndax price target raised to $37 from $35 at Barclays
- Phil Nadeau Reiterates Buy on Syndax, Citing Strong Revuforj Momentum, Longer Treatment Durations, and Emerging Niktimvo Upside
- Syndax reports Q1 EPS (48c), consensus (59c)